Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

Inclusion Criteria:

Patients must have had first menses >= 6 months prior to enrollment
Patients must be newly diagnosed with lymphoma; this includes but is not limited to Hodgkin lymphoma, Burkitts lymphoma, diffuse large B cell lymphoma, and anaplastic large cell lymphoma
Planned cancer treatment must include an alkylating agent: i.e. procarbazine, cyclophosphamide, ifosphamide; planned cancer treatment must be less than one year
Patients with any performance status are eligible for enrollment
Patients may take hormone medications excluding gonadotropin-releasing hormone (GnRH) analogues
All patients and/or their parents or legal guardians must sign a written informed consent
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Exclusion Criteria:

Patients who have previously received chemotherapy other than steroids and intrathecal chemotherapy are not eligible
Patients who have a secondary malignancy are not eligible
Patients with known history of ovarian disease: e.g. Turner syndrome or polycystic ovarian syndrome are not eligible
Patients in whom planned therapy includes: removal or uterus or ovary(ies), pelvic irradiation, cranial irradiation or hematopoietic stem cell transplantation are not eligible
Patients who previously have had their uterus or ovary(ies) removed are not eligible
Patients who have received gonadotropin release hormone agonist or antagonist (e.g. Lupron) prior to study entry are not eligible
Patients who are pregnant or breast feeding are not eligible
Patients who have undergone or are planning to undergo ovarian tissue, oocyte or embryo cryopreservation prior to treatment are not eligible